These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38709312)

  • 1. Patient reported outcomes and patient experiences of immune checkpoint modulators for advanced or recurrent melanoma: a mixed methods study.
    Tometich DB; Geiss C; Maconi ML; Chavez M; Hoogland AI; Li X; Nieves-Lopez A; Rodriguez Y; Bryant C; Brohl AS; Eroglu Z; Markowitz J; Tarhini AA; Hwu P; Khushalani NI; Jim HSL
    Support Care Cancer; 2024 May; 32(6):330. PubMed ID: 38709312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs.
    Hansen AR; Ala-Leppilampi K; McKillop C; Siu LL; Bedard PL; Abdul Razak AR; Spreafico A; Sridhar SS; Leighl N; Butler MO; Hogg D; Sacher A; Oza AM; Al-Agha R; Maurice C; Chan CT; Shapera S; Feld JJ; Nisenbaum R; Webster K; Cella D; Parsons J
    Cancer; 2020 Apr; 126(7):1550-1558. PubMed ID: 31914209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer patients' experiences with immune checkpoint modulators: A qualitative study.
    Ala-Leppilampi K; Baker NA; McKillop C; Butler MO; Siu LL; Spreafico A; Abdul Razak AR; Joshua AM; Hogg D; Bedard PL; Leighl N; Oza AM; Parsons JA; Hansen AR
    Cancer Med; 2020 May; 9(9):3015-3022. PubMed ID: 32119767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors.
    Mamoor M; Postow MA; Lavery JA; Baxi SS; Khan N; Mao JJ; Rogak LJ; Sidlow R; Thom B; Wolchok JA; Korenstein D
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32152222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. i-Move, a personalised exercise intervention for patients with advanced melanoma receiving immunotherapy: a randomised feasibility trial protocol.
    Hyatt A; Gough K; Murnane A; Au-Yeung G; Dawson T; Pearson E; Dhillon H; Sandhu S; Williams N; Paton E; Billett A; Traill A; Andersen H; Beedle V; Milne D
    BMJ Open; 2020 Feb; 10(2):e036059. PubMed ID: 32114479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
    Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
    JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study.
    Qian DC; Kleber T; Brammer B; Xu KM; Switchenko JM; Janopaul-Naylor JR; Zhong J; Yushak ML; Harvey RD; Paulos CM; Lawson DH; Khan MK; Kudchadkar RR; Buchwald ZS
    Lancet Oncol; 2021 Dec; 22(12):1777-1786. PubMed ID: 34780711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Organ-specific accuracy of [
    Gideonse BM; Birkeland M; Vilstrup MH; Grupe P; Naghavi-Behzad M; Ruhlmann CH; Gerke O; Hildebrandt MG
    Jpn J Radiol; 2024 Jul; 42(7):753-764. PubMed ID: 38504000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Learning about and living with toxicity: a qualitative study of patients receiving immune checkpoint inhibitors for melanoma or lung cancer and their caregivers.
    Falade AS; Boulanger MC; Hsu K; Sarathy R; Fadden R; Reynolds KL; Traeger L; Temel JS; Greer JA; Petrillo LA
    Support Care Cancer; 2024 Sep; 32(10):684. PubMed ID: 39320566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
    Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
    JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-related quality of life in survivors of advanced melanoma treated with anti-PD1-based immune checkpoint inhibitors.
    Looman EL; Cheng PF; Lai-Kwon J; Morgan L; Wakkee M; Dummer R; Dimitriou F
    Cancer Med; 2023 Jun; 12(11):12861-12873. PubMed ID: 37119050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of New Primary Cutaneous Melanoma in Patients With Metastatic Melanoma Treated With Immune Checkpoint Inhibitors: A Single-Center Cohort Study.
    Nanda JK; Dusza SW; Navarrete-Dechent C; Liopyris K; Marghoob AA; Marchetti MA
    JAMA Dermatol; 2021 Jan; 157(1):79-83. PubMed ID: 32936222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy.
    Ghisoni E; Wicky A; Bouchaab H; Imbimbo M; Delyon J; Gautron Moura B; Gérard CL; Latifyan S; Özdemir BC; Caikovski M; Pradervand S; Tavazzi E; Gatta R; Marandino L; Valabrega G; Aglietta M; Obeid M; Homicsko K; Mederos Alfonso NN; Zimmermann S; Coukos G; Peters S; Cuendet MA; Di Maio M; Michielin O
    Eur J Cancer; 2021 May; 149():153-164. PubMed ID: 33865201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frontline BRAF Testing-Guided Treatment for Advanced Melanoma in the Era of Immunotherapies: A Cost-Utility Analysis Based on Long-term Survival Data.
    Wu B; Shi L
    JAMA Dermatol; 2020 Nov; 156(11):1177-1184. PubMed ID: 32697281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy Outcomes in Advanced Melanoma in Relation to Age.
    Joshi K; Atwal D; Ravilla R; Pandey Y; Yarlagadda N; Kakadia S; Makhoul I; Hutchins L; Mahmoud F
    Perm J; 2020; 24():. PubMed ID: 32097116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
    Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
    Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Checkpoint Blockade in Melanoma Patients With Underlying Chronic Lymphocytic Leukemia.
    Smithy JW; Pianko MJ; Maher C; Postow MA; Shoushtari AN; Momtaz P; Chapman PB; Wolchok JD; Park JH; Callahan MK
    J Immunother; 2021 Jan; 44(1):9-15. PubMed ID: 33290361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.